igfbp3  (Cell Signaling Technology Inc)

Journal: Journal of Translational Medicine

Article Title: Novel insights into hypoxia-driven transcriptomic and epigenetic landscapes in grade 3 meningioma

doi: 10.1186/s12967-025-07606-9

Figure Lengend Snippet: Hypoxia-responsive gene signatures identified in grade 3 meningioma. ( A ) Significant differentially expressed genes in hypoxic versus normoxic IOMM-Lee cells; volcano plot depicting the upregulated and downregulated genes under Hypoxic versus Normoxic conditions in IOMM-Lee (Grade 3 Meningioma cell line). ( B ) Cluster heatmap of DEGs showing top 25 upregulated and downregulated genes. The color transition from blue to red indicates a change from downregulation to upregulation. ( C , D ) RT-qPCR validation of gene expression changes at 6, 24, 48 h under hypoxic conditions (0.2% O₂). (*p-value < 0.05; **p-value < 0.01; ***p-value < 0.001). ( E , F ) Upregulation of IGFBP3 and NDRG1 at protein level under hypoxia (0.2% O₂) at 48 h

Article Snippet: IGFBP3 specific siRNA was purchased from MedChemExpress (Cat. No. HY-RS06626, pre-designed siRNA).

Techniques: Quantitative RT-PCR, Biomarker Discovery, Gene Expression

Journal: Journal of Translational Medicine

Article Title: Novel insights into hypoxia-driven transcriptomic and epigenetic landscapes in grade 3 meningioma

doi: 10.1186/s12967-025-07606-9

Figure Lengend Snippet: IGFBP3 expression positively correlates with VEGFA and regulates meningioma cell viability and migration. (A–B) Correlation of IGFBP3 and NDRG1 expression with VEGFA in meningioma patients. ( C ) RT-qPCR validation of IGFBP3 across tumor grades and recurrent vs. non-recurrent cases. (D) Confirmation of IGFBP3 downregulation at the protein level upon IGFBP3 siRNA transfection via western blotting ( n = 2) ( E ) IGFBP3 depletion reduces meningioma cell viability. ( F-G ) Wound-healing assay showing reduced migration upon IGFBP3 silencing

Article Snippet: IGFBP3 specific siRNA was purchased from MedChemExpress (Cat. No. HY-RS06626, pre-designed siRNA).

Techniques: Expressing, Migration, Quantitative RT-PCR, Biomarker Discovery, Transfection, Western Blot, Wound Healing Assay

Journal: Signal Transduction and Targeted Therapy

Article Title: PKC-eta promotes breast cancer metastasis by regulating the Hippo–YAP signaling pathway

doi: 10.1038/s41392-026-02572-0

Figure Lengend Snippet: AKT phosphorylation of the upstream kinase cascade of the Hippo pathway is negatively regulated by PKCη. a Western blot analysis showing the activation of members of the upstream kinase cascade of the Hippo pathway, which is regulated by AKT phosphorylation, in PKCη KO TNBC cells. PKCη promotes YAP and PTEN expression, leading to dephosphorylation and inactivation of AKT. b An AKT inhibitor (MK-2206) effectively inhibits the upstream Hippo pathway phospho-cascade regulated by AKT in PKCη KO TNBC cells. c YAP-specific siRNA downregulates PTEN expression in TNBC cells in conjunction with AKT activation. d Relative mRNA expression of PTEN and PRKCH in control and MDA-MB-231 PKCη KO cells, as determined by RT‒qPCR. Knockout of PKCη in MDA-MB-231 cells resulted in a marked reduction in PTEN transcript levels compared with those in control cells. e Impact of PKCη expression on YAP transcriptional targets in TNBC cells. f Relative mRNA expression of canonical YAP target genes ( AXL, CYR61, IGFBP3 , and TEAD ) was measured via RT‒qPCR in MDA-MB-231 PKCη KO and control cells. PKCη knockout results in a significant reduction in the expression of these downstream effectors. g Schematic illustration of how YAP activity regulates PTEN expression and modulates the AKT pathway through this feedback mechanism (in the presence or absence of PKCη). Statistical significance was determined via two-way ANOVA, where * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001

Article Snippet: The antibodies used in this study were against YAP (CST, #14074), MST1 (CST, #3682), pMST1 (CST, #3681), LATS1 (CST, #3477), 14-3-3 ζ/δ (CST, #7413), pLATS1 (CST, #8654), pYAP (Ser127) (CST, #13008), pYAP (Ser109) (CST, #53749), pYAP (Ser397) (CST, #13619), pTAZ (Ser89) (CST, #75275), TAZ (CST, #83669), PTEN (CST, #9559) Lamin B1 (CST, #13435), AKT (pan) (CST, #4691), AXL (CST, #8661), Pan-TEAD (CST, #13295), CYR61 (CST, 14479), IGFBP3 (CST, #25864), HA-Tag (CST, #3724), FLAG (CST, #14793), pAKT (Ser473) (CST, #4060), and Anti-rabbit IgG (CST, # 7074).

Techniques: Phospho-proteomics, Western Blot, Activation Assay, Expressing, De-Phosphorylation Assay, Control, Knock-Out, Activity Assay